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Katherine A. Gallagher, MD,a Margaret Clarke Tracci, MD, JD,b and Sherry D. Scovell, MD,c Ann Arbor,
Mich; Charlottesville, Va; and Boston, Mass
The vasculitides are multiple clinical disease states that are characterized by inﬂammation of the wall of blood vessels.
They are typically classiﬁed by the size of the vessel that is affected. Some of the vasculitides are more commonly identiﬁed
in women, such as the large-vessel vasculitides. In addition, the incidence of some of the medium and small-vessel
vasculitides in women has increased during the past several decades. These inﬂammatory conditions speciﬁcally affecting
women will be reviewed here. The implications that pregnancy may have on various vasculitides will also be
highlighted. (J Vasc Surg 2013;57:27S-36S.)Vasculitides are a group of disorders that are character-
ized by inﬂammation and tissue necrosis within the wall
of a blood vessel. It is this inﬂammatory process that leads
to symptoms, most often due to stenosis or occlusion of
the vessel lumen. Vasculitides are categorized as primary,
for which there is most often an unknown etiology, or
secondary, in which there is typically an underlying disease
or trigger that can be identiﬁed. Primary vasculitides are
further classiﬁed by the size of the vessel involved, with
subgroups being those with large vessel involvement,
such as the aorta and its branches, medium vessel involve-
ment, or small-vessel involvement.
Some vasculitides are more commonly identiﬁed in
women, such as giant cell arteritis (GCA) and Takayasu
arteritis (TA). In addition, ﬁbromuscular dysplasia (FMD)
is a disease that mimics vasculitis and is more common in
women. Many of the vasculitides in medium and small
vessels have been historically more prevalent in men.
However, polyarteritis nodosa (PAN), Wegener granulo-
matosis (WG), and thromboangiitis obliterans (TAO),
otherwise known as Buerger disease, have seen an increase
in the overall percentage of women affected. This review
will highlight those vasculitides that are most prevalent in
women as well as those that demonstrate a trend toward
an increase in women. Vasculitis in pregnancy is an issue
that will also be reviewed.
LARGE-VESSEL VASCULITIDES
GCA. GCA, also known as temporal arteritis, predom-
inantly affects patients aged >50 years. It is the mostthe Division of Vascular and Endovascular Surgery, University of
ichigan Medical Center, Ann Arbora; the Division of Vascular and
dovascular Surgery, University of Virginia Health System, Charlottes-
lleb; and the Division of Vascular and Endovascular Surgery, Massachu-
tts General Hospital, Harvard Medical School, Boston.c
or conﬂict of interest: none.
rint requests: Sherry D. Scovell, MD, MGH/North Shore Center for
utpatient Care, 104 Endicott St, Ste 200, Danvers, MA 01923
-mail: sscovell@partners.org).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2013 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2012.10.119common vasculitis affecting Caucasians. Similar to other
autoimmune diseases, GCA affects women at a 2.5-fold
to 3-fold higher rate than men. The mean age of onset
of symptoms is 70 years.1,2 With respect to epidemiology,
there is a positive correlation between latitude and inci-
dence. Various organisms have been postulated to trigger
GCA; to date, however, no infectious etiology has been
deﬁnitively linked to development of the disease.3
The pathologic hallmark of the disease is granuloma-
tous inﬂammation of the medium and large vessels. The
media is the most frequently affected layer, although all
three layers can be inﬂamed. The inﬂammation most often
occurs in the superﬁcial temporal, ophthalmic, and verte-
bral arteries. The most common symptom seen with the
disease is headache, affecting 60%. The most severe compli-
cations of the disease are optic neuropathies, with resultant
vision loss and ischemic stroke. These complications are
due to intimal proliferation and occlusion rather than
thrombosis.4 Although risk factors for these catastrophic
events have yet to be deﬁned, elevated platelet counts,
jaw claudication, and amaurosis fugax are all reported risk
factors for permanent visual loss.5,6 These patients also
have higher rates of aortic involvement, occurring in 15%
of GCA patients as a late manifestation of the disease.7-9
A temporal artery biopsy specimen is the gold standard
for diagnosis. The presence of giant cells has been shown to
correlate with intimal proliferation. Corticosteroids are the
treatment of choice for the disease. Usually, prednisolone is
given at doses of 40 to 80 mg/d for 1 month and then
tapered to 20 mg/d as a maintenance dose. Two random-
ized controlled trials have been conducted to compare
methotrexate with corticosteroids, each arriving at opposite
conclusions.10,11
TA. TA is a large-vessel vasculitis affecting the aorta and
its primary branches and may lead to arterial segmental
stenosis, occlusion, or aneurysm formation. This disease is
signiﬁcantly more predominant in women, with a female-
to-male ratio of 8:1.12-14 In contrast to GCA, TA is
a disease of younger people, with age <40 years being one
of the classiﬁcation criteria for the condition.2,15 The
American College of Rheumatology has identiﬁed six major
criteria for the diagnosis of this disorder. (Table I). The
presence of three or more of these criteria is needed for
diagnosis. Small subsets of patients experience a self-limiting27S
Table I. Diagnostic criteria for the diagnosis of Takayasu
arteritis (TA)a,b
1. Development of symptoms before the age of 40 years.
2. Claudication of the upper extremities.
3. Decreased brachial artery pulse.
4. Blood pressure difference of >10 mm Hg between arms.
5. Bruit in subclavian artery.
6. Angiographic evidence of narrowing or occlusion of the
aorta, primary branches, or large arteries in the proximal
upper or lower extremities not due to atherosclerosis or
FMD.
FMD, Fibromuscular dysplasia.
aIf at least three of these criteria are present, the diagnosis of TA can be
made with a sensitivity of 90.5% and speciﬁcity of 97.8%.
bCriteria are based on the American College of Rheumatology 1990
Guidelines.
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long therapy; however, predicting this subset of patients is
not currently possible. Visual disturbances (10%), as well as
transient ischemic attack (20%) and stroke (5%) are known
to occur in these patients.4 Although most lesions occur in
the proximal segments of arteries arising from the transverse
aortic arch, the incidence of aortic valve regurgitation is 13%
to 25%. Many patients respond to corticosteroids; however,
relapses or steroid dependence often necessitates the use of
combination therapy with azathioprine and metho-
trexate.16-20
Patients with TA are challenging with regard to the
selection of appropriate surgical candidates and in the tech-
nical aspects of the operation. Although medical manage-
ment of acute disease and delayed surgical intervention
until acute inﬂammation has subsided is preferable, urgent
neurologic symptoms or uncontrolled hypertension may
prompt operative intervention. Surgery for brachiocephalic
trunk disease is infrequently necessary and limited to these
with neurologic symptoms, severe upper extremity claudica-
tion, and occasionally, those with severe bilateral carotid
stenosis.9,20,21 In addition, aortic and renal procedures
may be required for extreme cases of uncontrolled hyperten-
sion.22,23 Splanchnic vessel involvement is uncommon;
however, patients with visceral ischemiamay require surgical
intervention.
FMD. FMD is considered a disease of children and
young women of childbearing age and is the most
common cause for secondary hypertension in this popula-
tion.9,24,25 Of patients with identiﬁed FMD, renal
involvement occurs in 60% to 75%, cerebrovascular
involvement occurs in 25% to 30%, visceral involvement
occurs in 9%, and arteries of the limbs are affected in
w5%.26 Disease is found in more than one arterial region
in 26% of patients. Women aged 20 to 60 years are the
most commonly affected group and often present with
recalcitrant hypertension.
There are three main types of renal artery FMD
(RAFMD). Medial ﬁbroplasia is the most common type,
accounting for 80% of cases.27,28 Bilateral RA involvement
occurs in one-third of patients.29 The disease is rarelyassociated with loss of renal function, although progression
of stenosis has been shown to occur in 37%.24,25,30 Diag-
nostic angiography remains the gold standard for diagnosis.
The characteristic “string-of-beads” appearance on angi-
ography is associated with the medial type of RAFMD,
whereas focal narrowing is seen with the intimal type of
RAFMD.28,31,32 Recent technologic advances, speciﬁcally
the use of intravascular ultrasound imaging, have signiﬁ-
cantly improved the diagnosis and treatment of the disease.
Intravascular ultrasound imaging allows for accurate sizing
of the balloons as well as an accurate assessment of the
severity of stenosis.32 When treatment is recommended
for patients with recurrent hypertension or worsening renal
function, endovascular therapy with balloon angioplasty is
the preferred modality. Technical success rates of 100%
have been reported; however, clinical success rates, deﬁned
as improvement of hypertension, are much lower, ranging
from 21% to 72%. Accurate balloon sizing, without
oversizing, is crucial for prevention of rupture during
angioplasty.
Cerebrovascular FMD is the second most com-
mon location for FMD and is predominantly a disease
of women, occurring at a ratio of approximately 3:1 to
4:1.25 In those patients with cerebrovascular FMD, the
internal carotid artery is most often involved (95%), usually
at the C1-C2 level.33 In an additional one-third, the verte-
bral artery is involved. Cerebrovascular FMD is frequently
associated with intracranial aneurysms, and although the
link between FMD and aneurysms is not well deﬁned,
the reason for this phenomenon is possibly related to an
underlying connective tissue problem that results in loss
of arterial wall strength.25,28 FMD is an important cause
of stroke in young adults, especially young women. Most
patients with craniocervical FMD are asymptomatic.
Others report nonspeciﬁc problems such as headache,
lightheadedness, vertigo, and tinnitus. Neck pain may be
an initial presenting symptom in patients with arterial
dissection. The symptoms of stroke can be varied but
most often involve the anterior circulation. The gold stan-
dard for diagnosis is conventional angiography. Similar to
renal FMD, lesions typically show a beading pattern on
angiography. Four-vessel angiography should always be
performed because of the high incidence of multiple vessel
involvement.
The treatment of choice for uncomplicated cerebro-
vascular FMD is antiplatelet therapy. Percutaneous an-
gioplasty is the standard treatment for symptomatic
cerebrovascular FMD. Stents are used only when dissec-
tion occurs and is symptomatic.32 If arterial dissection is
identiﬁed and is asymptomatic, then anticoagulation is
the treatment of choice. This has not been well studied;
however, based on limited literature, anticoagulation
therapy should continue for 3 to 6 months. Some neurol-
ogists advocate the use computed tomography angiog-
raphy or magnetic resonance angiography to reassess of
the arteries before discontinuation of anticoagulation.
Other groups have recommended antiplatelet therapy
continue indeﬁnitely.32
Table II. Criteria for the diagnosis of polyarteritis nodosa (PAN)
1. Weight loss >4 kg: Loss of >4 kg body weight since illness began, not related to dieting or other factors.
2. Livedo reticularis: Mottled reticular pattern over the skin of portions of the extremities or torso.
3. Testicular pain/tenderness: Pain or tenderness of the testicles, not due to infection, trauma, or other causes.
4. Myalgias, weakness, or leg tenderness: Diffuse myalgias (excluding shoulder or hip girdle) or weakness of muscles or
tenderness of leg muscles.
5. Mononeuropathy or polyneuropathy: Development of mononeuropathy, multiple mononeuropathies, or polyneuropathy.
6. Diastolic blood pressure >90 mm Hg: Development of hypertension with the diastolic blood pressure >90 mm Hg.
7. Elevated blood urea nitrogen or creatinine: Elevation of blood urea nitrogen >40 mg/dL or creatinine >1.5 mg/dL,
not due to dehydration or obstruction.
8. Arteriographic abnormality: Arteriogram showing aneurysms or occlusions of the visceral arteries, not due to arteriosclerosis,
FMD, or other noninﬂammatory causes.
9. Hepatitis B virus: Presence of hepatitis B surface antigen or antibody in serum.
10. Biopsy specimen of small or medium-sized artery containing polymorphonuclear cells: Histologic changes showing
the presence of granulocytes or granulocytes and mononuclear leukocytes in the artery wall.
FMD, Fibromuscular dysplasia.
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PAN. PAN was ﬁrst described in 1866 by Kussmaul
and Maier,34 who noted arterial nodules during the
autopsy of a patient who had presented with systemic
symptoms. The 1994 Chapel Hill Consensus Conference
deﬁned PAN as necrotizing inﬂammation of medium or
small arteries in the absence of glomerulonephritis or
vasculitis in arterioles, capillaries, or venules.35 Classically,
men are affected twice as often as women, with the onset on
symptoms in the ﬁfth to sixth decades of life.36 However,
a recent series from Lugo, Spain, noted that men did not
predominate in their population of patients and that the
disease may also have a later onset in women.37 PAN is
generally idiopathic, although an association with hepatitis
B infection (HBV) has been established. Several cases of
presumed HBV vaccine–associated vasculitis, thought to
potentially represent immune complex disease, have been
reported to the Vaccine Adverse Event Reporting System
(VAERS).38
The American College of Rheumatology 1990 criteria
for the classiﬁcation of PAN reported a sensitivity of 82.2%
and speciﬁcity of 86% in distinguishing PAN from other
vasculitides. According to these criteria, vasculitis should
be classiﬁed as PAN if at least three of 10 speciﬁed criteria
are present39 (Table II). As suggested by these criteria,
systemic symptoms, such as fever, weight loss, myalgias,
and arthralgias are common, as are neurologic manifesta-
tions, including peripheral neuropathy or mononeuritis
multiplex. Serious renal and gastrointestinal complications
are less common but are associated with a poor prognosis.
Cardiovascular involvement may range from cardiomyop-
athy to digital ischemia. Classic vascular ﬁndings include
multiple visceral aneurysms. Peripheral, coronary, intracra-
nial, and end-organ (renal, hepatic) aneurysms have also
been reported.40 The erythrocyte sedimentation rate may
also be markedly elevated. Perinuclear antineutrophilic
cytoplasmic antibodies may be present. Other laboratory
ﬁndings may demonstrate end-organ effects, such as renal
dysfunction.41
Corticosteroids are ﬁrst-line therapy in the treatment of
PAN, with the addition of cyclophosphamide in severe orrefractory cases and with the addition of antiviral agents
and possibly plasma exchange for HBV-associated
PAN.42 Anti-tumor necrosis factor agents and intravenous
immunoglobulin infusions remain investigational. Aneu-
rysms may be treated as needed by open ligation with
or without revascularization or, as is becoming more
common, with endovascular modalities such as emboliza-
tion or stent graft exclusion.41,43,44
SMALL-VESSEL VASCULITIDES
The antineutrophil cytoplasmic autoantibody-
associated vasculitides. WG, Churg-Strauss syndrome
(CSS), and microscopic polyangiitis (MPA) typically affect
small vessels and are collectively known as antineutrophil
cytoplasmic autoantibody (ANCA)-associated vasculitides, or
AAVs. The Chapel Hill Consensus Conference presented
a system of nomenclature in 1994 to establish uniform deﬁ-
nitions for PAN and the AAVs35 (Table III). There has been
a recent move to substitute “granulomatosis with poly-
angiitis” for WG, driven by a general desire to move from
eponyms to pathology-based terminology but also inﬂuenced
by growing controversy surrounding Dr Wegener’s associa-
tion with the Nazi regime before and during World War II.
Under a pathology-based terminology, CSS is identiﬁed as
eosinophilic granulomatosis with polyangiitis.45,46
The ANCA-associated vasculitides continue to be
considered primary, idiopathic entities. However, epidemio-
logic studies have identiﬁed potential geographic, ethnic,
genetic, environmental, occupational, and infectious associa-
tions, suggesting multifactorial contributions to the develop-
ment of disease.47 The overall annual incidence of PAN and
AAVs is estimated at between 10 and 20 cases/million pop-
ulation. Available data are skewed by the predominance of
white, European populations (United Kingdom, Australia,
Spain, Sweden, Finland, Norway, and United States) in the
research populations and the paucity of data regarding
African, South Asian, and other non-Western groups.47
WG is a systemic, necrotizing small-vessel vasculitis.
The initial case was reported by Klinger in 1931; however,
Friedrich Wegener ultimately characterized the disease
through clear delineation of the clinical and pathologic
Table IV. Criteria for the classiﬁcation of Wegener
granulomatosis (WG)a,b,c
1. Nasal or oral inﬂammation: Development of painful or
painless oral ulcers or purulent or bloody nasal discharge.
2. Abnormal chest radiograph: Chest radiograph shows the
presence of nodules, ﬁxed inﬁltrates, or cavities.
3. Urinary sediment: Microhematuria (>5 red blood cells per
high-power ﬁeld) or red cell casts in urine sediment.
4. Granulomatous inﬂammation on biopsy specimen: Histologic
changes show granulomatous inﬂammation within the wall
of an artery or in the perivascular or extravascular area
(artery or arteriole).
aNeed two of four criteria for diagnosis. The presence of any two or more
criteria yields a sensitivity of 88.2% and a speciﬁcity of 92.0%.
bAmerican College of Rheumatology 1990 criteria.
cLeavitt et al.53
Table III. Deﬁnitions of vasculitidesa
1. Polyarteritis nodosa (PAN): Necrotizing inﬂammation of medium-sized or small arteries without glomerulonephritis or vasculitis
in arterioles, capillaries, or venules.
2. Wegener granulomatosis (WG): Granulomatous inﬂammation involving the respiratory tract and necrotizing vasculitis affecting
small-sized to medium-sized vessels (eg, capillaries, venules, arterioles, and arteries). Necrotizing glomerulonephritis is common.
3. Churg-Strauss syndrome (CSS): Eosinophil-rich and granulomatous inﬂammation involving the respiratory tract and necrotizing
vasculitis affecting small-sized to medium-sized vessels and associated with asthma and blood eosinophilia.
4. Microscopic polyangiitis (MSA): Necrotizing vasculitis with few or no immune deposits affecting small vessels (ie, capillaries,
venules, or arterioles). Necrotizing arteritis of small-sized and medium-sized arteries may be present. Necrotizing
glomerulonephritis is very common. Pulmonary capillaritis often occurs.
aChapel Hill Consensus Conference on the nomenclature of systemic vasculitis.
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documented to equally affect both men and women, or
even to be slightly male-predominant.48,49 However, the
study from Lugo, Spain, observed a higher incidence in
women, much like that seen in PAN in that population
of patients.50 A group of North American patients were
also noted to have a slightly increased prevalence in women
(56%), as in the Spanish cohort, with this group of patients
presenting with an earlier onset (age, 9-40 years).51
The Chapel Hill Consensus Conference deﬁnitions
do not constitute diagnostic criteria, leaving clinicians to
rely largely on the American College of Rheumatology’s
1990 diagnostic criteria for PAN, CSS, and WG39,52,53
(Tables IV and V). Because the application of these criteria
creates a great deal of overlap among PAN and the AAVs,
a stepwise algorithm has been created for the classiﬁca-
tion of these vasculitides.54 Immunologically, perinuclear
ANCA is characteristic of CSS and MPA, whereas cyto-
plasmic ANCA is typically associated with WG. Histologic
features may also aid in distinguishing among the AAVs.
Eosinophilia is a prominent feature of CSS, as reﬂected
in the proposed pathology-based nomenclature, and is
apparent in the white blood cell differential and in biopsy
specimens.
Clinically, respiratory symptoms predominate in CSS,
from asthma to pulmonary inﬁltrates and sinus symptoms.
ANCA status may affect presentation: the French Vasculitis
Study Group found that ANCA-positive CSS patients were
more likely to have renal and neurologic disease, whereas
the ANCA-negative group demonstrated more frequent
cardiac involvement.55 MPA was once considered a micro-
scopic form of PAN and currently lacks its own set of ACR
diagnostic criteria. Many now consider MPA to be part of
the clinical spectrum of WG, without the granulomatous
histologic ﬁndings typical of that entity. Renal and pulmo-
nary involvement is common in MPA.
The mainstay of treatment of AAV is immunosuppres-
sion. The initial focus is induction of remission, most
commonly with corticosteroids and oral cyclophospha-
mide. Remission may be maintained with a reduced dose
of corticosteroids and, potentially, with alternatives to
cyclophosphamide such as azathioprine, methotrexate, or
mycophenolate mofetil.56 Therapeutic agents under inves-
tigation, primarily for the treatment of refractory disease,
include antitumor necrosis factor agents, such as etanerceptor inﬂiximab, rituximab (anti-CD20 monoclonal anti-
body), and intravenous immunoglobulin.57
ANCA measurements are important in establishing the
diagnosis of AAV but are of limited utility in predicting
relapse or tracking the course of disease.58 Several instru-
ments have been developed to formalize the clinical assess-
ment of disease activity and severity in order to guide
optimal therapy. These include the Birmingham Vasculitis
Activity Score for all AAVs, the Birmingham Vasculitis
Activity Score for WG and the Disease Extent Index to
assess WG, and the Vascular Damage Index and ANCA-
associatedVasculitis Index ofDamage to quantify end-organ
damage.59 Also appropriate are system-speciﬁc investiga-
tions, such as urine studies and serum creatinine to assess
renal dysfunction, chest radiography to assess pulmonary
disease, nerve conduction studies for peripheral neuropathy,
or echocardiography to assess myocardial or valvular
dysfunction.
Patients with AAVs may be more prone to thrombotic
or thromboembolic events, whether as a consequence of
vessel damage or of prothrombotic factors. An increased
incidence of venous thrombotic events was recently
observed among patients with WG.60
TAO. TAO, also referred to as Buerger disease, is
a segmental, nonatherosclerotic inﬂammatory disorder. It
is classiﬁed under vasculitis of the medium vessels because
it primarily affects the medium and small vessels. TAO
was initially described by Von Winiwarter in 1879.
Table V. Criteria for the classiﬁcation of Churg-Strauss
syndrome (CSS)a,b,c
1. Asthma: History of wheezing or diffuse high-pitched
expiratory rhonchi.
2. Eosinophilia: Eosinophilia >10% on differential white blood
cell count.
3. Mononeuropathy or polyneuropathy: Development of
mononeuropathy, multiple mononeuropathies, or
polyneuropathy (glove/stocking distribution) attributable
to systemic vasculitis.
4. Pulmonary inﬁltrates, nonﬁxed: Migratory or transitory
pulmonary inﬁltrates (not including ﬁxed inﬁltrates) due
to vasculitis.
5. Paranasal sinus abnormality: History of acute or chronic
paranasal sinus pain or tenderness or radiographic
opaciﬁcation of the paranasal sinuses.
6. Extravascular eosinophils: Biopsy specimen including artery,
arteriole, or venule showing accumulations of eosinophils
in extravascular areas.
aClassiﬁed as CSS if at least four of six criteria are present.
bAmerican College of Rheumatology 1990 criteria.
cMasi et al.52
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description of the pathologic alterations associated with
the disease, which he studied from the vessels of amputated
limbs in 1908.
The annual incidence of TAO in the United States was
reported as 12.6 persons/100,000 in 1986, which has
decreased from the incidence of 104 persons/100,000
noted in 1947.61 TAO is most prevalent in patients who
are of Middle Eastern and Far Eastern origin. The proto-
typical patient is a man with a history of tobacco use,
usually aged <45 years. However, the disease may also
be seen in women, and in addition, an increase in the inci-
dence of TAO in women has been noted. Several studies
have reported an increase in the prevalence of the disease
in women ranging from 11% to 23%.61 Interestingly, the
prevalence of TAO in Asian women with a history of
tobacco use is quite low.62 Historically, between 1964
and 1970, the rate of TAO in women in one series was
5%. Between the years 1970 and 1995, it rose to 9.3%.
From 1995 to 2001, it remained relatively stable, at
9.8%.63 Sasaki et al64 demonstrated that the age at initial
diagnosis was higher in women than in men (42.9 vs
39.8 years).
The cause of TAO remains largely unknown, although
the use of tobacco clearly plays a central role in the disease
process and progression.65 Numerous studies have iden-
tiﬁed an extremely strong association between tobacco
use and TAO, and many clinicians believe that smoking
(either currently smoking or a history of smoking) is
a mandatory clinical factor for diagnosis.66 There is also
strong evidence of a cell-mediated immune response
affecting arteries and veins. In the acute phase, this is char-
acterized by inﬂammatory inﬁltration of the internal elastic
lamina, with a transition in the cellular composition of this
response in the chronic phase. The role of ANCA, antien-
dothelial cell antibodies, and antielastin antibodies is alsobeing investigated, as is an apparent association of TAO
with the presence of the prothrombotic G20210A
prothrombin gene mutation. Ultimately, the impairment
in endothelial-dependent relaxation of the peripheral
vessels and other typical ﬁndings of TAO appear to result
from a multifactorial etiology resulting from the interplay
of environmental, hereditary, and immune factors.67
Several sets of criteria have been developed for the di-
agnosis of TAO. Shionoya’s68 criteria include (1) smoking
history; (2) onset of symptoms before age 50 years;
(3) infrapopliteal arterial occlusions; (4) either arm involve-
ment or phlebitis migrans; and (5) absence of atheroscle-
rotic risk factors other than smoking. Olin’s61 criteria
include (1) age <45 years; (2) present or recent history
of tobacco use; (3) presence of distal extremity ischemia
(claudication, pain at rest, ischemic ulcers or gangrene)
documented by noninvasive vascular testing; (4) exclusion
of autoimmune diseases, hypercoagulable states, and dia-
betes mellitus; (5) exclusion of a proximal source of emboli
by echocardiography or arteriography; and (6) consistent
arteriographic ﬁndings in the clinically involved and nonin-
volved limbs. The scoring system proposed by Papa and
Adar66 assigns points to positive and negative criteria and
deﬁnes the diagnosis as deﬁnite if 6 or more points are
present, probable if 4 to 5, suspected if 2 to 3, and excluded
if #1.
Typical arteriographic lesions are described as corkscrew-
shaped collaterals, known as Martorell’s sign, which may
represent compensatory changes in vasa vasorum, in the pres-
ence of segmental lesions, or in occlusions in the distal
extremity. Although the distal extremities are typically
affected, there are rare reports of visceral, renal, aortoiliac,
and intracranial manifestations.67 Ischemic pain and tissue
loss present a signiﬁcant challenge in this population.
Smoking cessation is signiﬁcantly associated with
a reduced risk of amputation. Interestingly, however,
an equivalent beneﬁt may not be achieved in long-term
survival, which in one large study appeared to remain
signiﬁcantly lower than expected despite this interven-
tion.69 Pharmacotherapy has largely been limited to the
generalized recommendation of antiplatelet therapy and
the use, in Europe, of prostanoids, most notably intrave-
nous iloprost, which may offer pain relief beneﬁts. There
are mixed data on the beneﬁt of iloprost for ulcer healing.
Several studies have also suggested that bosentan, an oral
endothelin receptor antagonist, may be of beneﬁt.70
Owing to the very distal nature of the occlusive lesions,
reconstruction is frequently not possible. If technically
feasible, however, revascularization may, even with limited
patency, be helpful in healing ischemic lesions. The role of
open, laparoscopic, thoracoscopic, or chemical lumbar or
cervicothoracic sympathectomy in the treatment of refrac-
tory ischemic pain and nonhealing ulcers is controversial.
There are positive and negative reports in the literature
on the presence of clinical beneﬁt with regard to pain
control or wound healing. At least one study of microcir-
culation in TAO patients failed to show an immediate
improvement in lower extremity microcirculation after
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has also been reported.72 Several reports of clinical
improvement with the use of implantable spinal cord stim-
ulators have also been published.73
Raynaud’s phenomenon. Primary and secondary Ray-
naud’s phenomenon (RP) are the favored terms for the
group of vasospastic phenomena previously known, respec-
tively, as Raynaud’s disease, denoting primary, idiopathic
vasospastic digital ischemia, or Raynaud’s phenomenon,
which typically referred to digital vasospasm secondary to
other disorders74 (Table VI). The classic presentation is
that of digital ischemia associated with excessive sympa-
thetic activation and linked with triggers such as cold or
emotional distress. Although the documented prevalence of
primary RP varies widely among geographic and ethnic
populations, it is consistently more common in women.
The gender prevalence is much more marked in white than
in African American or Asian populations. The degree
of variation has been proposed to reﬂect differences
based on ethnicity, climate, and diagnostic methodology.74
Secondary RP does not, per se, carry a gender association,
but it is quite common in several disorders, such as sclero-
derma and systemic lupus erythematosus, that dispropor-
tionately affect women. Erythromelalgia and acrocyanosis
are, like RP, functional vascular disorders. Erythromelalgia
manifests as painful, paroxysmal burning pain of the feet or
hands associated with color changes and, occasionally, even
tissue loss. Acrocyanosis presents as painless, bilateral, dusky
discoloration of the hands and feet. Both, like RP, affect
women signiﬁcantly more frequently than men.75
The pathophysiology of RP is that of enhanced vaso-
constriction, impaired vasodilation, and modulation of the
adrenoreceptor response. The sympathetic component is
mediated by norepinephrine and stimulation of a-2 recep-
tors. There may be modulation of a-1 and a-2 receptor
responses in RP. Vasoconstriction is further favored by
increased endothelin-1 activity in these patients and, poten-
tially, increased activity of vasoconstrictor cyclooxygenase
factors, such as prostaglandins and thromboxane, and an
altered response to 5-hydroxytryptophan. Similarly, there
appears to be impairment of vasodilation through nitric
oxide-mediated pathways and other pathways.76
The diagnosis of primary RP is one of exclusion: the
typical episodic attacks of digital ischemia must be present
without any physical examination or laboratory evidence
of secondary causes77 (Table VII). A history of digital
ischemia combined with the presence of any of the factors
associated with secondary RP is strongly suggestive of that
diagnosis; otherwise, primary RP may be diagnosed.
Younger age and female gender are typically associated
with primary RP. The physical examination may suggest
a prominent subclavian pulse suggestive of arterial thoracic
syndrome, which may result in aneurysm formation and
distal emboli, as well as evidence of occlusive disease of
the more distal arteries. Examination of the hands may
demonstrate evidence of emboli or connective tissue dis-
ease, both suggesting secondary RP. Capillary microscopy,
if abnormal, also suggests secondary RP associated withscleroderma/systemic sclerosis.78 Special note should be
taken of evidence of active or healed ulcers.
Noninvasive vascular studies offer an assessment of the
presence and level of upper extremity arterial occlusive
disease. Finger pressures, particularly in conjunction with
the use of a cold challenge test involving assessment of
recovery after cold (4C) water immersion, are also useful
in establishing the diagnosis of RP.
Primary and secondary RP demonstrate a substantially
different natural history. Whereas primary RP is typiﬁed by
a benign course that rarely progresses to tissue loss and by
relatively frequent spontaneous remission, secondary RP
is more commonly progressive over time and associated
with signiﬁcant complications. The initial management of
primary and uncomplicated secondary RP includes risk
factor modiﬁcation: avoiding cold exposure, emotional
stress, and other possible environmental triggers such as
smoking or caffeine. Medications associated with vaso-
spasm or secondary RP should, if possible, be discontinued.
Biofeedback, aimed at developing learned control of au-
tonomic functions to increase skin perfusion, appears to
beneﬁt a subset of primary RP patients.
First-line pharmacologic treatment consists of dihydro-
pyridine calcium-channel blockers, of which nifedipine is
the most widely used. Oral or topical preparations of nitro-
glycerin have also been used effectively. Losartan, an angio-
tensin II receptor antagonist, has shown beneﬁt, as has
prazosin, an a-1–adrenergic blocker. For more severe or
refractory disease, intravenous infusion of the prostaglandin
iloprost has been associated with reduced attack severity,
duration, and frequency, as well as improved ulcer healing.
Bosentan, an oral endothelin receptor antagonist, has
shown beneﬁt in several European studies in the prevention
of new digital ulcers and healing of existing ulcers in
patients with RP secondary to systemic sclerosis. Several
studies have also suggested symptomatic improvement or
improved ulcer healing with the use of the phosphodies-
terase type 5 inhibitors sildenaﬁl, tadalaﬁl, and vardenaﬁl.
The potential role of serotonin receptor antagonists, sero-
tonin reuptake inhibitors, and antioxidants, such as N-ace-
tylcysteine, is under investigation.79
Several interventional therapies for severe RP aim to
directly disrupt the neural pathways involved in vasospasm.
These range from open or surgical lumbar or cervicothora-
cic, digital, or chemical sympathectomy to interdigital
injection of botulinum toxin-A. The role of lumbar or cer-
vicothoracic sympathectomy remains controversial, because
reported results are inconsistent and beneﬁts may not prove
durable over time. Surgical sympathectomy is generally
reserved for severe, refractory cases.80-82 Implantable spinal
cord stimulators have also shown promise in managing
ischemic pain associated with severe RP.83,84
VASCULITIS IN PREGNANCY
Although uncommon, vasculitis in pregnancy is an
important topic because several of the above-mentioned
vasculitides may occur with some frequency during the
childbearing years. To achieve an uncomplicated
Table VII. Criteria for the diagnosis of primary
Raynaud’s phenomenon (RP)a
1. Vasospastic attacks precipitated by cold or emotional stress.
2. Symmetric attacks involving both hands.
3. Absence of tissue necrosis or gangrene.
4. No history or physical ﬁndings suggestive of a secondary
cause.
5. Normal nail-fold capillaries.
6. Normal erythrocyte sedimentation rate.
7. Negative serologic ﬁndings, particularly negative test for
antinuclear antibodies.
aLeRoy et al.77
Table VI. Conditions associated with secondary Raynaud’s phenomenon (RP)
1. Connective tissue diseases: Scleroderma, rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease,
dermatomyositis, small- and medium-vessel vasculitis.
2. Arterial occlusive disease: Atherosclerotic arterial occlusive disease, TAO (Buerger disease), embolic disease.
3. Hematologic: malignancy (multiple myeloma, adenocarcinoma, leukemia, astrocytoma), polycythemia vera, cryoglobulinemia,
cold agglutinin disease.
4. Drug-induced: b-blockers, clonidine, ergot alkaloids, chemotherapeutic agents (bleomycin, vinca alkaloids, cisplatin, interferon-a),
drugs of abuse (cocaine, amphetamine), nicotine.
5. Traumatic: vibrational arteriopathy, hypothenar hammer syndrome, thoracic outlet syndrome (neurogenic or arterial), carpal
tunnel syndrome.
TAO, Thromboangiitis obliterans.
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advised to plan for conception when their disease is inac-
tive. The prepregnancy goal is to induce and maintain
remission throughout the pregnancy. It is also critical to
identify remission early when it does occur and treat with
the least toxic pharmaceutic agent. Many of the drugs
used to treat the vasculitides are toxic and may be terato-
genic to the fetus. In addition, many patients with vasculitis
have an increased risk of thromboembolic events, as does
the state of pregnancy itself. Thus, the main objectives
when treating a pregnant woman with vasculitis would
include prepregnancy counseling, careful evaluation and
treatment of the vasculitis, and assessment of thrombotic
risk throughout the pregnancy.
Unfortunately, there is a paucity of data regarding
vasculitides and pregnancy and outcomes. This is because
vasculitides occur more commonly in men or in women
beyond their reproductive period.85 The limited literature
available regarding treatment of speciﬁc vasculitides during
pregnancy is discussed below.
TA. Because TA typically does affect women during
the childbearing years, most of the large volume data on
pregnancy and vasculitis focuses on TA.86 Recommenda-
tions for patients with TA include that patients be in
remission before conception, because the overall maternal
and fetal outcomes are affected adversely in patients with
active disease. A review of six case series found an overall
15% risk of abortion, and 8% of newborns were premature,
with 15% having low birth weight.87 Pregnancy outcome
has been noted to be adversely affected by several factors,
including active disease during early pregnancy, hyperten-
sion in the late gestational period, aortic or renal involve-
ment, and a delay in medical attention.88 Disease activity
should be monitored closely in a clinical manner and with
imaging, such as magnetic resonance imaging, as needed.
Several studies have noted that preeclampsia occurred in
nearly 40% to 50% of patients and, when present, conferred
higher maternal and fetal risk. Close monitoring of blood
pressure is critical when patients are in labor because the
risk of intracranial hemorrhage may be increased during
this time. Corticosteroids are the ﬁrst line of treatment,
followed by the least cytotoxic agent, such as azathioprine,
should this fail.
WG. WG typically does not affect women of child-
bearing age. The ﬁrst case of WG during pregnancy wasdescribed in 1970, and 42 pregnancies had been reported
in 33 patients as of 2010.89,90 The inﬂuence that WG
may have on pregnancy seems to be unpredictable and
related to the trimester when the symptoms ﬁrst occur.
Diagnosis should be based on clinical presentation,
imaging studies, and results of serologic analysis. Although
WG most commonly manifests clinically with symptoms
related to the upper airway, lungs, and kidneys, some
patients with WG have presented with digital ischemia.91
Relapse in pregnancy may be life-threatening and requires
aggressive medical management. As mentioned previously,
prognosis in patients with WG has greatly improved
through the combination of steroids and cyclophospha-
mide.49 Although the use of cyclophosphamide during
pregnancy has never been formally investigated, a few case
reports have documented an increase in the incidence of
spontaneous abortions as well as birth defects, which
become accentuated when this cytotoxic agent is used in
the ﬁrst trimester.92,93 When cyclophosphamide is used
after the ﬁrst trimester, however, the data suggest that fetal
tolerance improves signiﬁcantly.94-96 Often, intravenous
immunoglobulin may be used for patients presenting with
WG in the ﬁrst trimester or for the maintenance of
remission throughout pregnancy.97
CSS. CSS may affect women of childbearing age;
however, little has been published regarding pregnancy
and CSS. Several case reports suggest that respiratory and
cardiac symptoms present in 25% to 50% of pregnant
patients. Most often, patients experience asthma. However,
cardiac damage may be sufﬁciently severe as well as irrevers-
ible and can necessitate heart transplantation. Despite this,
67% to 80% of infants born to mothers with CSS were
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cardiac involvement had the poorest outcomes.98 Treat-
ment of CSS in pregnancy ranges from monotherapy with
corticosteroids to the addition of intravenous immuno-
globulin or a cytotoxic agent, such as cyclophosphamide.
PAN. The incidence of PAN tends to peak in the ﬁfth
decade; thus, there is a paucity of literature on PAN in
pregnant women. However, the few case reports available
indicate that patients who have been diagnosed with
PAN before pregnancy and remain in remission
throughout pregnancy seem to have fewer adverse events.
Conversely, gravid patients with newly diagnosed PAN
during pregnancy have higher rates of maternal death
due to renal failure, gastrointestinal hemorrhage, respira-
tory failure, and coma.99 Life-threatening disease requires
treatment with cytotoxic agents in combination with
corticosteroids.
The overall tenet in the management of women who
present with or experience a relapse of vasculitis is early
diagnosis and treatment with the least toxic agent appro-
priate to effectively treat the mother and protect the fetus.
CONCLUSIONS
Vasculitis in women is an issue that requires a multidis-
ciplinary approach to manage effectively. And interestingly,
several large studies have noted a rise in the incidence
of vasculitides in women during the last several decades.
Because some of the vasculitides presented here require
surgical or endovascular management at some point in
the disease process and may present with some type of
ischemia, it is critical for the vascular surgeon to be familiar
with these entities and their overall management.
AUTHOR CONTRIBUTIONS
Conception and design: KG, SS
Analysis and interpretation: KG, MT, SS
Data collection: KG, MT, SS
Writing the article: KG, MT, SS
Critical revision of the article: KG, MT, SS
Final approval of the article: SS
Statistical analysis: Not applicable
Obtained funding: Not applicable
Overall responsibility: KG, MT, SS
REFERENCES
1. Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE.
Reappraisal of the epidemiology of giant cell arteritis inOlmstedCounty,
Minnesota, over a ﬁfty-year period. Arthritis Rheum 2004;51:264-8.
2. Arnaud L, Haroche J, Limal N, Toledano D, Gambotti L, Costedoat
Chalumeau N, et al. Takayasu arteritis in France: a single-center
retrospective study of 82 cases comparing white, North African, and
black patients. Medicine (Baltimore) 2010;89:1-17.
3. Russo MG, Waxman J, Abdoh AA, Serebro LH. Correlation between
infection and the onset of the giant-cell (temporal) arteritis syndrome—
a trigger mechanism? Arthritis Rheum 1995;38:374-80.
4. Park MC, Lee SW, Park YB, Chung NS, Lee SK. Clinical characteristics
and outcomes of Takayasu’s arteritis: analysis of 108 patients using
standardized criteria for diagnosis, activity assessment, and angio-
graphic classiﬁcation. Scand J Rheumatol 2005;34:284-92.5. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, Martinez-
Taboada VM, Delgado-Rodriguez M, Figueroa M, et al. Permanent
visual loss and cerebrovascular accidents in giant cell arteritis: predictors
and response to treatment. Arthritis Rheum 1998;41:1497-504.
6. Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, et al.
Risk factors for visual loss in giant cell (temporal) arteritis: a prospective
study of 174 patients. Am J Med 2001 Aug 15;111:211-7.
7. Gonzalez-Gay MA, Blanco R, Sanchez-Andrade A, Vazquez-
Caruncho M. Giant cell arteritis in Lugo, Spain: a more frequent
disease with fewer classic features. J Rheumatol 1997;24:2166-70.
8. Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, Pego-Reigosa R,
Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with
biopsy-proven giant cell arteritis from northwestern Spain: a pop-
ulation-based study. Medicine 2004;83:335-41.
9. Lande A. Takayasu’s arteritis and congenital coarctation of descending
thoracic and abdominal-aorta—critical-review. Am J Roentgenol
1976;127:227-33.
10. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH,
Schousboe J, et al; International Network for the Study of Systematic
Vasculitides. A multicenter, randomized, double-blind, placebo-
controlled trial of adjuvant methotrexate treatment for giant cell
arteritis. Arthritis Rheum 2002;46:1309-18.
11. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A,
Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with
methotrexate and prednisone. Ann Intern Med 2001;134:106-14.
12. Koide K. Takayasu arteritis in Japan. Heart Vessels Suppl 1992;7:48-54.
13. Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F. Clinical
manifestations of Takayasu arteritis in India and Japan—new classiﬁ-
cation of angiographic ﬁndings. Angiology 1997;48:369-79.
14. Numano F. Differences in clinical presentation and outcome in
different countries for Takayasu’s arteritis. Curr Opin Rheumatol
1997;9:12-5.
15. Ladhani S, Tulloh R, Anderson D. Takayasu disease masquerading as
interruption of the aortic arch in a 2-year-old child. Cardiol Young
2001;11:244-6.
16. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of
therapy and a guarded prognosis in an American cohort of Takayasu
arteritis patients. Arthritis Rheum 2007;56:1000-9.
17. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W,
et al. EULAR recommendations for the management of primary small
and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
18. Fraga A, Mintz G, Valle L, Flores-Izquierdo G. Takayasu’s arteritis:
frequency of systemic manifestations (study of 22 patients) and favor-
able response to maintenance steroid therapy with adrenocorticoste-
roids (12 patients). Arthritis Rheum 1972;15:617-24.
19. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J,
Horwitz S, Vela JE. Takayasu’s arteritis. Clinical study of 107 cases.
Am Heart J 1977;93:94-103.
20. Nakao K, Ikeda M, Kimata S, Niitani H, Niyahara M. Takayasu’s
arteritis. Clinical report of eighty-four cases and immunological studies
of seven cases. Circulation 1967;35:1141-55.
21. Tanabe T, Yokota A, Yasuda K. Pathogenesis and surgical treatment of
aortitis syndrome. Jpn Circ J 1982;46:194-200.
22. Lagneau P, Michel JB. Renovascular hypertension and Takayasu’s
disease. J Urol 1985;134:876-9.
23. Teoh PC, Tan LK, Chia BL, Chao TC, Tambyah JA, Feng PH. Non-
speciﬁc aorto-arteritis in Singapore with special reference to hyperten-
sion. Am Heart J 1978;95:683-90.
24. Olin JW, Sealove BA. Diagnosis, management, and future develop-
ments of ﬁbromuscular dysplasia. J Vasc Surg 2011;53; 826-36.e1.
25. Slovut DP, Olin JW. Fibromuscular dysplasia. N Engl J Med 2004;350:
1862-71.
26. Luscher TF, Keller HM, Imhof HG, Greminger P, Kuhlmann U,
Largiader F, et al. Fibromuscular hyperplasia: extension of the disease
and therapeutic outcome. Results of the University Hospital Zurich
Cooperative Study on Fibromuscular Hyperplasia. Nephron
1986;44(Suppl 1):109-14.
27. Harrison EG Jr, McCormack LJ. Pathologic classiﬁcation of renal
arterial disease in renovascular hypertension. Mayo Clin Proc 1971;46:
161-7.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 4S Gallagher et al 35S28. Stanley JC, Gewertz BL, Bove EL, Sottiurai V, Fry WJ. Arterial ﬁbro-
dysplasia—histopathologic character and current etiologic concepts.
Arch Surg 1975;110:561-6.
29. Davies MG, Saad WE, Peden EK, Mohiuddin IT, Naoum JJ,
Lumsden AB. The long-term outcomes of percutaneous therapy for
renal artery ﬁbromuscular dysplasia. J Vasc Surg 2008;48:865-71.
30. Schreiber MJ, Pohl MA, Novick AC. The natural history of athero-
sclerotic and ﬁbrous renal artery disease. Urol Clin North Am 1984;11:
383-92.
31. Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheu-
matol 2000;12:41-7.
32. Olin JW. Recognizing and managing ﬁbromuscular dysplasia. Cleve
Clin J Med 2007;74:273-4; 277-82.
33. Mettinger KL, Ericson K. Fibromuscular dysplasia and the brain. I.
Observations on angiographic, clinical and genetic characteristics.
Stroke 1982;13:46-52.
34. Kussmaul A, Maier K. Ueber eine nicht bisher beschriebene eigen-
humliche Arterienerkrankung (Periarteritis Nodosa), die mit Morbus
Brightii und rapid fortschreitender allgemeiner Muskellahmung ein-
hergeht. Dtsch Arch Klin Med 1866;1:484-518.
35. Jennette JC, Falk RJ, Andressy K, Bacon PA, Churg J, Gross WL, et al.
Nomenclature of systemic vasculitides. Proposal of an international
consensus conference. Arthritis Rheum 1994;37:187-92.
36. Conn DL. Polyarteritis. Rheum Dis Clin North Am 1990;16:341-62.
37. Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in
Northwestern Spain, 1988-1997. Clinical and epidemiological aspects.
Medicine (Baltimore) 1999;78:292-308.
38. Begier EM, Langford CA, Sneller MC, Wise RP, Ball R; VAERS
Working Group. Polyarteritis nodosa reports to the Vaccine Adverse
Events Reporting System (VAERS): implications for assessment of
suspected vaccine-provoked vasculitis. J Rheum 2004;31:2181-8.
39. Lightfoot RW, Michel BA, Bloch DA, Hunder GG, Zvaiﬂer NJ,
McShane DJ, et al. The American College of Rheumatology 1990
criteria for the classiﬁcation of polyarteritis nodosa. Arthritis Rheum
1990;33:1088-93.
40. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al.
Clinical features and outcomes in 348 patients with polyarteritis
nodosa: a systematic retrospective study of patients diagnosed between
1963 and 2005 and entered into the French vasculitis study group
database. Arthritis Rheum 2010;62:616-26.
41. Adajar MA, Painter T, Woloson S, Memark V. Isolated celiac artery
aneurysm with splenic artery stenosis as a rare presentation of poly-
arteritis nodosum: a case report and review of the literature. J Vasc Surg
2006;44:647-50.
42. deMenthon M, Mahr A. Treating polyarteritis nodosa: current state of
the art. Clin Exper Rheum 2011;29(1 Suppl 64):S110-6.
43. Sellke FM, Williams GB, Donovan DL, Clarke RE. Management of
intra-abdominal aneurysms associated with periarteritis nodosa. J Vasc
Surg 1986;4:294-8.
44. Kasirajan K, Greenberg RK, Clair D, Ouriel K. Endovascular
management of visceral artery aneurysm. J Endovasc Ther 2001;8:
150-5.
45. Falk RJ, Gross WL, Guillevin L, Hoffman G, Jayne DR, Jennette JC,
et al. Granulomatosis with polyangiitis (Wegener’s): an alternative name
for Wegener’s granulomatosis. Letter. Ann Rheum Dis 2011;70:704.
46. Berden A, Göçeroglu A, Jayne D, Luqmani R, Rasmussen N,
Bruijn JA, et al. Diagnosis and management of ANCA associated
vasculitis. BMJ 2012;344:e 26.
47. Ntatsaki E, Watts RA, Scott DG. Epidemiology of ANCA-associated
vasculitis. Rheum Dis Clin North Am 2010;36:447-61.
48. Carruthers DM, Watts RA, Symmons DP, Scott DG. Wegener’s
granulomatosis—increased incidence or increased recognition? Br J
Rheumatol 1996;35:142-5.
49. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS,
Travis WD, et al. Wegener’s granulomatosis: an analysis of 158
patients. Ann Intern Med 1992;116:448-98.
50. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P,
Llorca J. The epidemiology of the primary systemic vasculitides in
northwest Spain: implications of the Chapel Hill Consensus Confer-
ence deﬁnitions. Arthritis Rheum 2003;49:388-93.51. Abdou NI, Kullman GJ, Hoffman GS, Sharp GC, Specks U,
McDonald T, et al. Wegener’s granulomatosis: survey of 701 patients
in North America. Changes in outcome in the 1990s. J Rheumatol
2002;29:309-16.
52. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al.
The American College of Rheumatology 1990 criteria for the classiﬁ-
cation of Churg-Strauss syndrome (allergic granulomatosis and angii-
tis). Arthritis Rheum 1990;33:1094-100.
53. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP,
et al. The American College of Rheumatology 1990 criteria for the
classiﬁcation of Wegener’s granulomatosis. Arthritis Rheum 1990;33:
1101-7.
54. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W,
et al. Development and validation of a consensus methodology for the
classiﬁcation of the ANCA-associated vasculitides and polyarteritis
nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-7.
55. Sablé-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L,
Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-
Strauss syndrome. Ann Intern Med 2005;143:632-8.
56. Seo P, Stone JH. Small- and medium-vessel vasculitis. Arthritis Rheum
2007;57:1552-9.
57. Chung SA, Seo P. Advances in the use of biologic agents for the
treatment of systemic vasculitis. Curr Opin Rheumatol 2009;21:3-9.
58. Tomasson G, Grayson PC, Mahr AD, Lavalley M, Merkel PA. Value of
ANCA measurements during remission to predict a relapse of ANCA-
associated vasculitis—a meta-analysis. Rheum 2012;51:100-9.
59. Watts RA, Scott DG. Recent developments in the classiﬁcation and
assessment of vasculitis. Best Pract Res Clin Rheum 2009;23:429-43.
60. Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis JC Jr,
et al. Brief communication: high incidence of venous thrombotic events
among patients with Wegener granulomatosis: the Wegener’s Clinical
Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med
2005;142:620-6.
61. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J
Med 2000;343:864-9.
62. Lau H, Cheng SW. Buerger’s disease in Hong Kong: a review of 89
cases. Aust N Z J Surg 1997;67:264-9.
63. Yörükoglu Y, Ilgit E, Zengin M, Nazliel K, Salman E, Yucel E.
Thromboangiitis obliterans (Buerger’s disease) in women (a reevalua-
tion). Angiology 1993;44:527-32.
64. Sasaki S, Sakuma M, Kunihara T, Yasuda K. Current trends in
thromboangiitis obliterans (Buerger’s disease) in women. Ann J Surg
1999;177:316-20.
65. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Bartholomew JR. The
changing clinical spectrum of thromboangiitis obliterans (Buerger’s
disease). Circulation 1990;82(Suppl IV); IV-3-8.
66. Papa MZ, Adar R. A critical look at thromboangiitis obliterans
(Buerger’s disease). Perspect Vasc Surg Endovasc Ther 1992;5:1-18.
67. Malecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the
21st century—a new face of disease. Atherosclerosis 2009;206:328-34.
68. Shionoya S. What is Buerger’s disease? World J Surg 1983;7:544-51.
69. Cooper LT, Tse TS, Mikhail MA, McBane RD, Stanson AW,
Ballman KV. Long-term survival and amputation risk in thromboan-
giitis obliterans (Buerger’s disease). J Am Coll Cardiol 2004;44:
2410-1.
70. Todali Parra JA, Hernandez MM, Arrebola Lopez MA. Efﬁcacy of
bosentan in digital ischemic ulcers. Ann Vasc Surg 2010;24: 690.e1-4.
71. Nishikimi N, Sakurai T, Shionoya S, Oshima M. Microcirculatory
characteristics in patients with Buerger’s disease. Angiology 1992;43:
312-9.
72. Ala-Kulju K, Virkkula L. Use of omental pedicle for treatment of
Buerger’s disease affecting the upper extremities. A modiﬁed tech-
nique. Vasa 1990;19:330-3.
73. Swigris JJ, Olin JW, Mekhail NA. Implantable spinal cord stimulator to
treat the ischemic manifestations of thromboangiitis obliterans
(Buerger’s disease). J Vasc Surg 1999;29:928-35.
74. Wigley FM. Raynaud’s phenomenon. Curr Opin Rheumatol 1993;5:
773-84.
75. Heidrich H. Functional vascular diseases: Raynaud’s syndrome, acro-
cyanosis and erythromelalgia. Vasa 2010;39:33-41.
JOURNAL OF VASCULAR SURGERY
36S Gallagher et al April Supplement 201376. Cooke JP, Marshall JM. Mechanisms of Raynaud’s disease. Vasc Med
2005;10:293-307.
77. LeRoy EC, Medsger TA Jr. Raynaud’s phenomenon: a proposal for
classiﬁcation. Clin Exp Rheumatol 1992;10:485-8.
78. Anderson ME, Allen PD, Moore T, Hillier V, Taylor CJ, Herrick AL.
Computerized nailfold video capillaroscopy- a new tool for assessment
of Raynaud’s phenomenon. J Rheumatol 2005;32:841-8.
79. Levien TL. Advances in the treatment of Raynaud’s phenomenon.
Vasc Health Risk Mgmt 2010;6:167-77.
80. Coveliers HM, Hoexum F, Nederhoed JH, Wisselink W, Rauwerda JA.
Thoracic sympathectomy for digital ischemia: a summary of evidence.
J Vasc Surg 2011;54:273-7.
81. Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterial
sympathectomy. J Hand Surg Am 2009;34:1454-60.
82. Neumeister MW, Chambers CB, Herron MS, Webb K, Wietfeldt J,
Gillespie JN, et al. Botox therapy for ischemic digits. Plas Reconst Surg
2009;124:191-201.
83. Münster T, Tiebel N, Seyer H, Maihöfner C. Modulation of somato-
sensory proﬁles by spinal cord stimulation in primary Raynaud’s
syndrome. Pain Practice 2012;12:469-75.
84. Francaviglia N, Silvestro C, Maiello M, Bragazzi R, Bernucci C. Spinal
cord stimulation for the treatment of progressive systemic sclerosis and
Raynaud’s syndrome. Br J Neurosurg 1994;8:567-71.
85. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of
the twentieth century—a disease of older patients. Rheumatology
2005;44:495-501.
86. Doria A, Iaccarino L, Ghirardello A, Arienti S, Zampieri S,
Rampudda ME, et al. Rare autoimmune rheumatic illnesses during
pregnancy. Systemic sclerosis, polymyositis/dermatomyositis and
vasculitis. Z Rheumatol 2006;65:200-8.
87. Gasch O, Vidaller A, Pujol R. Takayasu arteritis and pregnancy from
the point of view of the internist. J Rheumatol 2009;36:1554-5.
88. Sharma BK, Jain S, Vasistha K. Outcome of pregnancy in Takayasu
arteritis. Int J Cardiol 2000;75:S159-62.89. Cooper K, Stafford J, Turner-Warwick M. Wegener’s granulomatosis
complicating pregnancy. J Obstet Gynaecol Br Commonw 1970;77:
1028-30.
90. Devakumar VN, Castelino M, Chow SC, Teh LS. Wegener’s gran-
ulomatosis in pregnancy: a case report and review of the medical
literature [published online ahead of print January 13, 2010]. BJM
Case Rep 2010. doi:10.1136/bcr.09.2009.2296.
91. Bessias N, Moulakakis KG, Lioupis C, Bakogiannis K, Sfyroeras G,
Kakaletri K, et al. Wegener’s granulomatosis presenting during preg-
nancy with acute limb ischemia. J Vasc Surg 2005;42:800-4.
92. Toledo TM, Harper RC, Moser RH. Fetal effects during cyclophos-
phamide and irradiation therapy. Ann Intern Med 1971;74:87-91.
93. Murray CL, Reichert JA, Anderson J, Twiggs LB. Multimodal cancer
therapy for breast cancer in the ﬁrst trimester of pregnancy. JAMA
1984;252:2607-8.
94. Talbot SF, Main DM, Levinson AI. Wegener’s granulomatosis: ﬁrst
report of a case with onset during pregnancy. Arthritis Rheum
1984;27:109-12.
95. Luisiri P, Lance NJ, Curren JJ. Wegener’s granulomatosis in preg-
nancy. Arthritis Rheum 1997;40:1354-60.
96. Dayoan ES, Dimen LL, Boylen CT. Successful treatment of Wegener’s
granulomatosis during pregnancy: a case report and review of the
medical literature. Chest 1998;113:836-8.
97. Harber MA, Tso A, Taheri S, Tuck SM, Burns A. Wegener’s gran-
ulomatosis in pregnancy—the therapeutic dilemma. Nephrol Dial
Transplant 1999;14:1789-91.
98. Corradi D, Maestri R, Facchetti F. Postpartum Churg-Strauss
syndrome with severe cardiac involvement: description of a case and
review of the literature. Clin Rheumatol 2009;28:739-43.
99. Pitkin RM. Polyarteritis nodosa. Clin Obstet Gynecol 1983;26:579-86.Submitted Mar 7, 2012; accepted Oct 26, 2012.
